Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street ZenMarket Beat·Aug 15 at 12:54 AMSVRA+3.91%BNPQY-1.71%
Savara merilis presentasi korporasi tentang penyakit paru langka autoimmune PAP dan kandidat terapi inhalasi MOLBREEVIPUBT·Aug 11 at 03:40 PMSVRA+3.91%
SVRA: MOLBREEVI shows strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. marketQuartr·Aug 11 at 03:34 PMSVRA+3.91%
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 | SVRA Stock NewsStockTitan·Jul 29 at 11:05 PMSVRA+3.91%
Savara posts corporate presentation focused on autoimmune pulmonary alveolar proteinosis and MOLBREEVI programPUBT·Jul 15 at 11:52 AMSVRA+3.91%
Savara (SVRA) Stock May Trade At A Premium On Pipeline ExpectationsSimplywall·Jul 8 at 07:18 AMSVRA+3.91%
Does FDA Review of MOLBREEVI and Insider Sales Shift the Bull Case For Savara (SVRA)?Simplywall·Jun 29 at 02:50 PMSVRA+3.91%
Is Savara (SVRA) Expensive As Its Rally Puts A Premium On Book Value?Simplywall·Jun 28 at 11:04 AMSVRA+3.91%
Savara CFO David Lowrance disposes of 580,187 common shares worth $3.31 millionPUBT·Jun 22 at 07:18 PMSVRA+3.91%
Savara Announces New Employment Inducement Grant | SVRA Stock NewsStockTitan·Jun 12 at 07:05 AMSVRA+3.91%
